Target intelligence / Profile preview

Squalene--hopene cyclase (SHC)

Target
SHC
Molecular classification
Enzyme, Intramolecular transferase, Isomerase, Triterpene cyclase, Membrane protein (monotopic)
01

Overview

Squalene--hopene cyclase (SHC) is a monotopic membrane-associated enzyme that catalyzes the extraordinary one-step cyclization of the linear triterpene squalene into pentacyclic hopene and, to a lesser extent, hopanol (diplopterol)[2][3][4][8]. This highly complex reaction forms five rings, nine stereocenters, and alters thirteen covalent bonds in a single enzymatic step[2][3]. SHC is widespread in bacteria and some plants, where it is essential for hopanoid biosynthesis—hopanoids are sterol-like molecules that help stabilize membranes, especially under stress[3][4]. The enzyme’s structure features a large, hydrophobic active-site cavity, lined with aromatic residues, and a nonpolar channel for substrate access[1][5]. Its mechanism is based on Brønsted acid catalysis, primarily utilizing an aspartate residue to initiate the polycyclization reaction cascade[4][5]. While SHC itself has not been directly targeted by clinically used drugs, it has been investigated as a template for developing antifungals and cholesterol-lowering agents due to its mechanistic and structural similarity to human oxidosqualene cyclase (lanosterol synthase)[4][6]. SHC serves as an important biocatalyst in synthetic chemistry for complex triterpene scaffolds[7].

Other names
Squalene hopene cyclaseSHCSqualene-hopanol cyclaseTriterpene cyclaseSQHC
02

Mechanism of action

Enzyme inhibitors (competitive active site binding), Transition-state analogs, Active-site-directed electrophiles[4].

03

Biological functions

Triterpene cyclizationConversion of squalene to hopene and hopanolSterol and hopanoid biosynthesisLipid metabolism
04

Disease associations

Other (primarily microbial physiology; roles as a direct target in human disease are not established)Potential indirect role in infection (as a target for antibacterial/antifungal agents)
05

Safety considerations

Not established for direct pharmacological targeting; potential for off-target effects in cholesterol biosynthetic pathways if cross-reactivity with homologous human enzymes (such as lanosterol synthase) occurs[4].
06

Interacting drugs

No approved drugs specifically target SHC in clinical use; enzyme inhibitors have been studied experimentally as antifungal and anticholesteremic leads[4].

Beyond the preview

Go deeper on Squalene--hopene cyclase (SHC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Squalene--hopene cyclase (SHC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call